MEMPHIS, TN - May 18, 2009 - ACORN CRO, an oncology -focused CRO, has developed proprietary technology known as STAR (Site Tracking And Recruitment). The introduction of this dedicated technology tool will speed the site selection process as it automates the study feasibility process. "STAR was developed under the guidance of ACORN CRO's experienced project managers who sought to save valuable time during the study start-up phase. The resulting system delivers solutions that provide meaningful cost benefits to both sponsors and participating sites," remarked Edward J. Stepanski, PhD, COO.
STAR increases transparency and efficiency in the study feasibility/site selection process. The Site Repository contains all known information about each oncology research site, and enables rapid selection of potential study sites based upon sponsor/study requirements. It also reduces the need for sites to complete repetitive tasks and is estimated to save approximately 75% of the time sites traditionally spend on com pleting study feasibility forms. Through STAR, sponsors are able to v iew a report summarizing site identification metrics in real time. Sponsors will appreciate that STAR automatically sends reminder notifications throughout the process, allows complete tracking of the status of each site contacted, and reduces the time needed to definitively identify study sites.
"STAR is yet another way in which ACORN CRO leverages technology to provide added value and efficiency for its customers. STAR substantially speeds up the study start-up process which results in impressive economies of scale," added Kristie Lively, Vice President.
ACORN CRO will showcase STAR at the annual DIA meeting in San Diego, June 22-24, 2009 in booth #2039.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.